European Journal of Heart Failure最新文献

英文中文

Burst steroid therapy for acute heart failure: The CORTAHF randomized, open-label, pilot trial 急性心力衰竭的类固醇脉冲疗法：CORTAHF 随机、开放标签试点试验

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure

Pub Date : 2024-08-30 DOI: 10.1002/ejhf.3452

Gad Cotter, Beth A. Davison, Yonathan Freund, Adriaan A. Voors, Christopher Edwards, Maria Novosadova, Koji Takagi, Hamlet Hayrapetyan, Andranik Mshetsyan, Drambyan Mayranush, Alain Cohen-Solal, Jozine M. ter Maaten, Jan Biegus, Piotr Ponikowski, Gerasimos Filippatos, Ovidiu Chioncel, Malha Sadoune, Matteo Pagnesi, Tabassome Simon, Marco Metra, Douglas L. Mann, Alexandre Mebazaa

Aims

Burst steroid therapy, effective in acute respiratory diseases, may benefit patients with acute heart failure (AHF) in whom inflammatory activation is associated with adverse outcomes.

Methods and results

CORTAHF assessed whether burst steroid therapy reduces inflammation and results in better quality of life and clinical outcomes in AHF. Patients with AHF, N-terminal pro-B-type natriuretic peptide >1500 pg/ml, and high-sensitivity C-reactive protein (hsCRP) >20 mg/L were randomized 1:1 to oral, once daily 40 mg prednisone for 7 days or usual care, without blinding. Patients were followed for 90 days. A total of 101 patients were randomized. At day 7 the primary endpoint, hsCRP decreased in both arms – adjusted geometric mean ratios (GMRs) were 0.30 and 0.40 in the prednisone and usual care arms (ratio of GMRs 0.75, 95% confidence interval [CI] 0.56–1.00, p = 0.0498). The 90-day risk of worsening heart failure (HF), HF readmission or death as reported by the unblinded investigators was significantly lower in the prednisone group (10.4%) than in usual care (30.8%) (hazard ratio 0.31, 95% CI 0.11–0.86, p = 0.016). The EQ-5D visual analogue scale score as reported by the unblinded patients increased more in the prednisone group on day 7 (least squares mean difference 2.57, 95% CI 0.12–5.01 points, p = 0.040). All effects were statistically significant in the pre-specified subgroup with centrally-measured interleukin-6 >13 pg/ml. Adverse events, particularly hyperglycaemia, occurred more in the prednisone group with no difference in infection rate.

Conclusion

In this small open-label study of patients with AHF, burst steroid therapy was associated with reduced inflammation as measured by hsCRP levels at day 7 (primary endpoint). Secondary endpoints showed improved quality of life at day 7 and reduced 90-day risk of death or worsening HF. Large prospective studies are needed to evaluate these findings.

方法和结果CORTAHF评估了类固醇爆发疗法是否能减轻炎症反应并改善急性心力衰竭患者的生活质量和临床预后。对患有 AHF、N-末端前 B 型钠尿肽（N-terminal pro-B-type natriuretic peptide）1500 pg/ml、高敏 C 反应蛋白（hsCRP）20 mg/L 的患者按 1:1 随机分配到口服 40 mg 痉化波尼松（prednisone），每天一次，连续 7 天或常规治疗，不设盲法。患者随访 90 天。共有 101 名患者接受了随机治疗。在主要终点第 7 天，两组患者的 hsCRP 均有所下降--泼尼松组和常规治疗组的调整后几何平均比 (GMR) 分别为 0.30 和 0.40（GMR 比值为 0.75，95% 置信区间 [CI]为 0.56-1.00，P = 0.0498）。根据非盲法研究者的报告，泼尼松组（10.4%）的 90 天心衰（HF）恶化、HF 再入院或死亡风险显著低于常规治疗组（30.8%）（危险比 0.31，95% CI 0.11-0.86，p = 0.016）。泼尼松组患者在第 7 天时的 EQ-5D 视觉模拟量表评分增加较多（最小二乘法均值差 2.57，95% CI 0.12-5.01 分，p = 0.040）。在中心测定的白细胞介素-6 >13 pg/ml的预设亚组中，所有影响均有统计学意义。在这项针对 AHF 患者的小型开放标签研究中，根据第 7 天时的 hsCRP 水平（主要终点）测量，爆发性类固醇治疗与炎症减轻有关。次要终点显示，第7天的生活质量得到改善，90天死亡或HF恶化的风险降低。需要进行大型前瞻性研究来评估这些发现。

{"title":"Burst steroid therapy for acute heart failure: The CORTAHF randomized, open-label, pilot trial","authors":"Gad Cotter, Beth A. Davison, Yonathan Freund, Adriaan A. Voors, Christopher Edwards, Maria Novosadova, Koji Takagi, Hamlet Hayrapetyan, Andranik Mshetsyan, Drambyan Mayranush, Alain Cohen-Solal, Jozine M. ter Maaten, Jan Biegus, Piotr Ponikowski, Gerasimos Filippatos, Ovidiu Chioncel, Malha Sadoune, Matteo Pagnesi, Tabassome Simon, Marco Metra, Douglas L. Mann, Alexandre Mebazaa","doi":"10.1002/ejhf.3452","DOIUrl":"10.1002/ejhf.3452","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Burst steroid therapy, effective in acute respiratory diseases, may benefit patients with acute heart failure (AHF) in whom inflammatory activation is associated with adverse outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and results</h3>\u0000 \u0000 <p>CORTAHF assessed whether burst steroid therapy reduces inflammation and results in better quality of life and clinical outcomes in AHF. Patients with AHF, N-terminal pro-B-type natriuretic peptide >1500 pg/ml, and high-sensitivity C-reactive protein (hsCRP) >20 mg/L were randomized 1:1 to oral, once daily 40 mg prednisone for 7 days or usual care, without blinding. Patients were followed for 90 days. A total of 101 patients were randomized. At day 7 the primary endpoint, hsCRP decreased in both arms – adjusted geometric mean ratios (GMRs) were 0.30 and 0.40 in the prednisone and usual care arms (ratio of GMRs 0.75, 95% confidence interval [CI] 0.56–1.00, <i>p</i> = 0.0498). The 90-day risk of worsening heart failure (HF), HF readmission or death as reported by the unblinded investigators was significantly lower in the prednisone group (10.4%) than in usual care (30.8%) (hazard ratio 0.31, 95% CI 0.11–0.86, <i>p</i> = 0.016). The EQ-5D visual analogue scale score as reported by the unblinded patients increased more in the prednisone group on day 7 (least squares mean difference 2.57, 95% CI 0.12–5.01 points, <i>p</i> = 0.040). All effects were statistically significant in the pre-specified subgroup with centrally-measured interleukin-6 >13 pg/ml. Adverse events, particularly hyperglycaemia, occurred more in the prednisone group with no difference in infection rate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this small open-label study of patients with AHF, burst steroid therapy was associated with reduced inflammation as measured by hsCRP levels at day 7 (primary endpoint). Secondary endpoints showed improved quality of life at day 7 and reduced 90-day risk of death or worsening HF. Large prospective studies are needed to evaluate these findings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"26 10","pages":"2282-2292"},"PeriodicalIF":16.9,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.3452","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142101950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between caseload volume and outcomes in left ventricular assist device implantations – a EUROMACS analysis 左心室辅助装置植入术的病例量与预后之间的关系--EUROMACS分析

IF 18.2 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure

Pub Date : 2024-08-29 DOI: 10.1002/ejhf.3418

Maks Mihalj, David Reineke, Isabell A. Just, Johanna Mulzer, Nikolaos Cholevas, Christoph Hoermandinger, Kevin Veen, Markus M Luedi, Paul Philipp Heinisch, Evgenij Potapov, Jan F. Gummert, Paul Mohacsi, Christian Hagl, Gloria Faerber, Daniel Zimpfer, Theo M.M.H. de By, Bart Meyns, Finn Gustafsson, Lukas Hunziker, Matthias Siepe, Patrick Schober, Felix Schoenrath

This EUROMACS study was conducted with the primary aim of investigating the association between a centre's annual caseload and postoperative outcomes among patients undergoing left ventricular assist device (LVAD) implantation.

这项 EUROMACS 研究的主要目的是调查接受左心室辅助装置（LVAD）植入术的患者中，中心的年接诊量与术后效果之间的关系。

引用次数: 0

For improving the prognosis of patients with left ventricular assist device: Beyond the evaluation of caseload volume 用于改善左心室辅助装置患者的预后：超越病例量评估

IF 18.2 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure

Pub Date : 2024-08-29 DOI: 10.1002/ejhf.3437

Naoki Sato

引用次数: 0

The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology 癌症患者的右心。ESC心力衰竭协会（HFA）和ESC肿瘤心脏病学委员会的科学声明。

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure

Pub Date : 2024-08-28 DOI: 10.1002/ejhf.3412

Kalliopi Keramida, Dimitrios Farmakis, Amina Rakisheva, Carlo Gabriele Tocchetti, Pietro Ameri, Riccardo Asteggiano, Ana Barac, Jeroen Bax, Antoni Bayes-Genis, Jutta Bergler Klein, Chiara Bucciarelli-Ducci, Jelena Celutkiene, Andrew J.S. Coats, Alain Cohen Solal, Susan Dent, Gerasimos Filippatos, Arjun Ghosh, Joerg Hermann, Yvonne Koop, Daniel Lenihan, Teresa Lopez Fernandez, Alexander R. Lyon, Valentina Mercurio, Brenda Moura, Massimo Piepoli, Yusuf Ziya Sener, Thomas Suter, Aaron L. Sverdlov, Marijana Tadic, Thomas Thum, Peter van der Meer, Sophie van Linthout, Marco Metra, Giuseppe Rosano

引用次数: 0

Contemporary trends of atrial fibrillation management in heart failure patients: Do we practice what we preach? 心力衰竭患者心房颤动管理的当代趋势：我们是否言行一致？

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure

Pub Date : 2024-08-27 DOI: 10.1002/ejhf.3431

Thomas Fink, Vanessa Sciacca, Paulus Kirchhof, Philipp Sommer

引用次数: 0

Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H2FPEF score 根据 H2FPEF 评分评估肥厚型心肌病患者的心衰风险。

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure

Pub Date : 2024-08-27 DOI: 10.1002/ejhf.3413

Dorien Laenens, Thomas Zegkos, Vasileios Kamperidis, Raymond C.C. Wong, Tony Yi-Wei Li, Ching-Hui Sia, William K.F. Kong, Georgios Efthimiadis, Kian Keong Poh, Antonios Ziakas, Jeroen J. Bax, Nina Ajmone Marsan

Aims

The aim of this study was to investigate whether the H₂FPEF score, which was developed to improve the diagnosis of heart failure (HF) with preserved ejection fraction, is associated with HF outcomes in patients with hypertrophic cardiomyopathy (HCM).

Methods and results

Patients with HCM and preserved left ventricular ejection fraction (LVEF ≥50%) were included from a multicentre registry and the H₂FPEF score was calculated. Patients were divided into three groups: low (0–1), intermediate (2–5) and high (6–9) H₂FPEF score. The primary combined endpoint was a composite of all-cause death and HF admissions, while the secondary endpoints were all-cause death and HF admissions separately. A total of 955 patients were included (age 51 ± 17 years, 310 [32.5%] female). Patients with a high H₂FPEF score (n = 105) were more often female, and presented with more symptoms and comorbidities. On echocardiography, patients with a high H₂FPEF score had lower LVEF, more impaired diastolic function and more frequently left ventricular outflow tract obstruction. During follow-up (median 90 months [interquartile range 49–176]), 103 (11%) patients died and 57 (6%) patients had a first HF hospitalization. Event-free survival rate for the primary combined and secondary endpoints was lower for patients with an intermediate and high H₂FPEF score. On multivariate Cox regression analysis, female sex (hazard ratio [HR] 1.670, 95% confidence interval [CI] 1.157–2.410; p = 0.006), Asian ethnicity (HR 6.711, 95% CI 4.076–11.048; p < 0.001), ischaemic heart disease (HR 1.732, 95% CI 1.133–2.650; p = 0.011), left atrial diameter (HR 1.028, 95% CI 1.005–1.051; p = 0.016) and intermediate (HR 2.757, 95% CI 1.612–4.713; p < 0.001) or high H₂FPEF score (HR 3.689, 95% CI 1.908–7.134; p < 0.001) were independently associated with the primary combined endpoint.

Conclusion

The H₂FPEF score is independently associated with HF outcome in patients with HCM and may be considered for risk stratification.

研究目的：H2FPEF评分是为改善射血分数保留型心力衰竭（HF）的诊断而开发的，本研究旨在探讨该评分是否与肥厚型心肌病（HCM）患者的HF预后相关：多中心登记处纳入了左室射血分数（LVEF ≥50%）保留的 HCM 患者，并计算了 H2FPEF 评分。患者被分为三组：H2FPEF 评分低（0-1 分）、中（2-5 分）和高（6-9 分）。主要综合终点是全因死亡和心房颤动入院的复合终点，次要终点分别是全因死亡和心房颤动入院。共纳入 955 例患者（年龄 51 ± 17 岁，女性 310 例 [32.5%]）。H2FPEF评分较高的患者（n = 105）多为女性，且症状和合并症较多。在超声心动图检查中，H2FPEF评分高的患者LVEF较低，舒张功能受损更严重，左室流出道梗阻更常见。在随访期间（中位数为 90 个月【四分位数间距为 49-176】），103 名（11%）患者死亡，57 名（6%）患者首次因心房颤动住院。H2FPEF得分中等和较高的患者在主要合并终点和次要终点的无事件生存率较低。在多变量 Cox 回归分析中，女性（危险比 [HR] 1.670，95% 置信区间 [CI] 1.157-2.410；P = 0.006）、亚裔（HR 6.711，95% CI 4.076-11.048；P 2FPEF 评分（HR 3.689，95% CI 1.908-7.134；P 结论：H2FPEF 评分与心房颤动无关：H2FPEF 评分与 HCM 患者的心房颤动预后密切相关，可用于风险分层。

{"title":"Heart failure risk assessment in patients with hypertrophic cardiomyopathy based on the H2FPEF score","authors":"Dorien Laenens, Thomas Zegkos, Vasileios Kamperidis, Raymond C.C. Wong, Tony Yi-Wei Li, Ching-Hui Sia, William K.F. Kong, Georgios Efthimiadis, Kian Keong Poh, Antonios Ziakas, Jeroen J. Bax, Nina Ajmone Marsan","doi":"10.1002/ejhf.3413","DOIUrl":"10.1002/ejhf.3413","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The aim of this study was to investigate whether the H<sub>2</sub>FPEF score, which was developed to improve the diagnosis of heart failure (HF) with preserved ejection fraction, is associated with HF outcomes in patients with hypertrophic cardiomyopathy (HCM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and results</h3>\u0000 \u0000 <p>Patients with HCM and preserved left ventricular ejection fraction (LVEF ≥50%) were included from a multicentre registry and the H<sub>2</sub>FPEF score was calculated. Patients were divided into three groups: low (0–1), intermediate (2–5) and high (6–9) H<sub>2</sub>FPEF score. The primary combined endpoint was a composite of all-cause death and HF admissions, while the secondary endpoints were all-cause death and HF admissions separately. A total of 955 patients were included (age 51 ± 17 years, 310 [32.5%] female). Patients with a high H<sub>2</sub>FPEF score (<i>n</i> = 105) were more often female, and presented with more symptoms and comorbidities. On echocardiography, patients with a high H<sub>2</sub>FPEF score had lower LVEF, more impaired diastolic function and more frequently left ventricular outflow tract obstruction. During follow-up (median 90 months [interquartile range 49–176]), 103 (11%) patients died and 57 (6%) patients had a first HF hospitalization. Event-free survival rate for the primary combined and secondary endpoints was lower for patients with an intermediate and high H<sub>2</sub>FPEF score. On multivariate Cox regression analysis, female sex (hazard ratio [HR] 1.670, 95% confidence interval [CI] 1.157–2.410; <i>p</i> = 0.006), Asian ethnicity (HR 6.711, 95% CI 4.076–11.048; <i>p</i> < 0.001), ischaemic heart disease (HR 1.732, 95% CI 1.133–2.650; <i>p</i> = 0.011), left atrial diameter (HR 1.028, 95% CI 1.005–1.051; <i>p</i> = 0.016) and intermediate (HR 2.757, 95% CI 1.612–4.713; <i>p</i> < 0.001) or high H<sub>2</sub>FPEF score (HR 3.689, 95% CI 1.908–7.134; <i>p</i> < 0.001) were independently associated with the primary combined endpoint.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The H<sub>2</sub>FPEF score is independently associated with HF outcome in patients with HCM and may be considered for risk stratification.</p>\u0000 </section>\u0000 </div>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"26 10","pages":"2173-2182"},"PeriodicalIF":16.9,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.3413","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142071557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glycolysis in heart failure with preserved ejection fraction. 射血分数保留型心力衰竭中的糖酵解。

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure

Pub Date : 2024-08-27 DOI: 10.1002/ejhf.3432

Gary D Lopaschuk, Qiuyu Sun, Ezra B Ketema

引用次数: 0

Dynamic evolution of tricuspid regurgitation during hospitalization in patients with acute decompensated heart failure. 急性失代偿性心力衰竭患者住院期间三尖瓣反流的动态演变。

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure

Pub Date : 2024-08-27 DOI: 10.1002/ejhf.3433

Eugenio Zocca, Daniele Cocianni, Davide Barbisan, Maria Perotto, Stefano Contessi, Jacopo Giulio Rizzi, Giulio Savonitto, Enrico Brollo, Elisa Soranzo, Antonio De Luca, Marco Merlo, Gianfranco Sinagra, Davide Stolfo

Aims: Secondary tricuspid regurgitation (TR) is associated with poor prognosis in acute decompensated heart failure (ADHF). However, its dynamic evolution in response to volume status and treatment has never been previously investigated. In this study, we sought to explore the in-hospital evolution of TR in ADHF patients and to assess its prognostic implications.

Methods and results: We retrospectively enrolled patients admitted for ADHF with ≥2 in-hospital echocardiographic evaluations of TR. Patients were categorized, according to TR evolution, into persistent moderate-severe TR, improved TR (from moderate-severe to trivial-mild) and persistent trivial-mild TR. The primary endpoint was a composite of 5-year all-cause mortality and heart failure hospitalization (HFH). A total of 1054 patients were included. Of 318 patients (30%) with moderate-severe TR at admission, 49% improved TR severity and showed better trends of decongestion, whereas those who maintained persistent moderate-severe TR had characteristics of more severe heart failure at admission and discharge. Atrial fibrillation, previous heart failure and higher dosage of loop diuretics before admission were associated with a lower probability of improved TR. After adjustment, improved TR was associated with lower risk of 5-year all-cause mortality/HFH compared with persistent moderate-severe TR (hazard ratio [HR] 0.524, p = 0.008) and no different from persistent trivial-mild TR (HR 0.878, p = 0.575). Results were consistent across all subgroups of in-hospital variation of mitral regurgitation.

Conclusion: Among ADHF patients with moderate-severe TR at admission, 49% had an in-hospital improvement in TR severity, which was associated with a reduction in risk of 5-year all-cause mortality and morbidity outcomes.

目的：继发性三尖瓣反流（TR）与急性失代偿性心力衰竭（ADHF）的不良预后有关。然而，以前从未研究过三尖瓣反流随容量状态和治疗的动态演变。在这项研究中，我们试图探讨 ADHF 患者 TR 在院内的演变情况，并评估其对预后的影响：我们回顾性地纳入了因 ADHF 入院、院内超声心动图评估 TR≥2 次的患者。根据TR的演变情况，将患者分为持续性中度-重度TR、TR改善（从中度-重度到轻度-微小）和持续性轻度-微小TR。主要终点是5年全因死亡率和心力衰竭住院率（HFH）的综合。共纳入了 1054 名患者。在入院时患有中度重度TR的318名患者（30%）中，49%的患者TR严重程度有所改善，并显示出更好的去充血趋势，而那些持续患有中度重度TR的患者在入院和出院时具有更严重的心衰特征。心房颤动、既往心衰和入院前服用较多环形利尿剂与TR改善的概率较低有关。经调整后，与持续性中度-重度 TR 相比，改善 TR 与较低的 5 年全因死亡率/HFH 风险相关（危险比 [HR] 0.524，p = 0.008），与持续性轻微-轻度 TR 无差异（HR 0.878，p = 0.575）。二尖瓣反流的院内变化在所有亚组中结果一致：结论：在入院时患有中度-重度TR的ADHF患者中，49%的患者院内TR严重程度有所改善，这与5年全因死亡率和发病率风险的降低有关。

{"title":"Dynamic evolution of tricuspid regurgitation during hospitalization in patients with acute decompensated heart failure.","authors":"Eugenio Zocca, Daniele Cocianni, Davide Barbisan, Maria Perotto, Stefano Contessi, Jacopo Giulio Rizzi, Giulio Savonitto, Enrico Brollo, Elisa Soranzo, Antonio De Luca, Marco Merlo, Gianfranco Sinagra, Davide Stolfo","doi":"10.1002/ejhf.3433","DOIUrl":"https://doi.org/10.1002/ejhf.3433","url":null,"abstract":"<p><strong>Aims: </strong>Secondary tricuspid regurgitation (TR) is associated with poor prognosis in acute decompensated heart failure (ADHF). However, its dynamic evolution in response to volume status and treatment has never been previously investigated. In this study, we sought to explore the in-hospital evolution of TR in ADHF patients and to assess its prognostic implications.</p><p><strong>Methods and results: </strong>We retrospectively enrolled patients admitted for ADHF with ≥2 in-hospital echocardiographic evaluations of TR. Patients were categorized, according to TR evolution, into persistent moderate-severe TR, improved TR (from moderate-severe to trivial-mild) and persistent trivial-mild TR. The primary endpoint was a composite of 5-year all-cause mortality and heart failure hospitalization (HFH). A total of 1054 patients were included. Of 318 patients (30%) with moderate-severe TR at admission, 49% improved TR severity and showed better trends of decongestion, whereas those who maintained persistent moderate-severe TR had characteristics of more severe heart failure at admission and discharge. Atrial fibrillation, previous heart failure and higher dosage of loop diuretics before admission were associated with a lower probability of improved TR. After adjustment, improved TR was associated with lower risk of 5-year all-cause mortality/HFH compared with persistent moderate-severe TR (hazard ratio [HR] 0.524, p = 0.008) and no different from persistent trivial-mild TR (HR 0.878, p = 0.575). Results were consistent across all subgroups of in-hospital variation of mitral regurgitation.</p><p><strong>Conclusion: </strong>Among ADHF patients with moderate-severe TR at admission, 49% had an in-hospital improvement in TR severity, which was associated with a reduction in risk of 5-year all-cause mortality and morbidity outcomes.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142078538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of ventricular-arterial coupling with biomarkers involved in heart failure pathophysiology - the STANISLAS cohort. 心室-动脉耦合与心力衰竭病理生理学相关生物标志物的关系--STANISLAS队列。

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure

Pub Date : 2024-08-27 DOI: 10.1002/ejhf.3411

Hannes Holm, Martin Magnusson, Amra Jujić, Jérémy Lagrange, Erwan Bozec, Zohra Lamiral, Emmanuel Bresso, Olivier Huttin, Guillaume Baudry, Luca Monzo, Patrick Rossignol, Faiez Zannad, Nicolas Girerd

Aims: Impaired left ventricular-arterial coupling (VAC) has been shown to correlate with worse prognosis in cardiac diseases and heart failure (HF). The extent of the relationship between VAC and circulating biomarkers associated with HF has been scarcely documented. We aimed to explore associations of VAC with proteins involved in HF pathophysiology within a large population-based cohort of middle-aged individuals.

Methods and results: In the forth visit of the STANISLAS family cohort, involving 1309 participants (mean age 48 ± 14 years; 48% male) from parent and children generations, we analysed the association of 32 HF-related proteins with non-invasively assessed VAC using pulse wave velocity (PWV)/global longitudinal strain (GLS) and arterial elastance (E_a)/ventricular end-systolic elastance (E_es). Among the 32 tested proteins, fatty acid-binding protein adipocyte 4, interleukin-6, growth differentiation factor 15, matrix metalloproteinase (MMP)-1, and MMP-9 and adrenomedullin were positively associated with PWV/GLS whereas transforming growth factor beta receptor type 3, MMP-2 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were negatively associated. In multivariable models, only MMP-2 and NT-proBNP were significantly and inversely associated with PWV/GLS in the whole population and in the parent generation. Higher levels of NT-proBNP were also negatively associated with E_a/E_es in the whole cohort but this association did not persist in the parent subgroup.

Conclusion: Elevated MMP-2 and NT-proBNP levels correlate with better VAC (lower PWV/GLS), possibly indicating a compensatory cardiovascular response to regulate left ventricular pressure amidst cardiac remodelling and overload.

目的：左心室-动脉耦合（VAC）受损已被证明与心脏疾病和心力衰竭（HF）的预后恶化相关。VAC 与心力衰竭相关循环生物标志物之间的关系程度还鲜有记录。我们的目的是在一个基于人群的大型中年人队列中探讨 VAC 与涉及高血压病理生理学的蛋白质之间的关系：在 STANISLAS 家族队列的第四次访问中，我们使用脉搏波速度（PWV）/全局纵向应变（GLS）和动脉弹性（Ea）/心室收缩末期弹性（Ees）分析了 32 种高血压相关蛋白质与非侵入性评估的 VAC 的关联。在检测的 32 种蛋白质中，脂肪酸结合蛋白脂肪细胞 4、白细胞介素-6、生长分化因子 15、基质金属蛋白酶（MMP）-1、MMP-9 和肾上腺髓质素与脉搏波速度/GLS 呈正相关，而转化生长因子 beta 受体 3 型、MMP-2 和 N 端前 B 型钠尿肽（NT-proBNP）呈负相关。在多变量模型中，只有 MMP-2 和 NT-proBNP 与整个人群和父代的脉搏波速度/GLS 显著成反比关系。在整个人群中，较高水平的NT-proBNP也与Ea/Ees呈负相关，但这种关联在父代亚组中并不存在：结论：MMP-2 和 NT-proBNP 水平升高与较好的 VAC（较低的 PWV/GLS）相关，这可能表明在心脏重塑和负荷过重的情况下调节左心室压力的代偿性心血管反应。

{"title":"Association of ventricular-arterial coupling with biomarkers involved in heart failure pathophysiology - the STANISLAS cohort.","authors":"Hannes Holm, Martin Magnusson, Amra Jujić, Jérémy Lagrange, Erwan Bozec, Zohra Lamiral, Emmanuel Bresso, Olivier Huttin, Guillaume Baudry, Luca Monzo, Patrick Rossignol, Faiez Zannad, Nicolas Girerd","doi":"10.1002/ejhf.3411","DOIUrl":"https://doi.org/10.1002/ejhf.3411","url":null,"abstract":"<p><strong>Aims: </strong>Impaired left ventricular-arterial coupling (VAC) has been shown to correlate with worse prognosis in cardiac diseases and heart failure (HF). The extent of the relationship between VAC and circulating biomarkers associated with HF has been scarcely documented. We aimed to explore associations of VAC with proteins involved in HF pathophysiology within a large population-based cohort of middle-aged individuals.</p><p><strong>Methods and results: </strong>In the forth visit of the STANISLAS family cohort, involving 1309 participants (mean age 48 ± 14 years; 48% male) from parent and children generations, we analysed the association of 32 HF-related proteins with non-invasively assessed VAC using pulse wave velocity (PWV)/global longitudinal strain (GLS) and arterial elastance (E<sub>a</sub>)/ventricular end-systolic elastance (E<sub>es</sub>). Among the 32 tested proteins, fatty acid-binding protein adipocyte 4, interleukin-6, growth differentiation factor 15, matrix metalloproteinase (MMP)-1, and MMP-9 and adrenomedullin were positively associated with PWV/GLS whereas transforming growth factor beta receptor type 3, MMP-2 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were negatively associated. In multivariable models, only MMP-2 and NT-proBNP were significantly and inversely associated with PWV/GLS in the whole population and in the parent generation. Higher levels of NT-proBNP were also negatively associated with E<sub>a</sub>/E<sub>es</sub> in the whole cohort but this association did not persist in the parent subgroup.</p><p><strong>Conclusion: </strong>Elevated MMP-2 and NT-proBNP levels correlate with better VAC (lower PWV/GLS), possibly indicating a compensatory cardiovascular response to regulate left ventricular pressure amidst cardiac remodelling and overload.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":16.9,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142071555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving the rate of heart failure with improved ejection fraction. 改善射血分数，提高心衰发生率。

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure

Pub Date : 2024-08-22 DOI: 10.1002/ejhf.3427

Evangelos Giannitsis, Norbert Frey, Pardeep S Jhund

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

European Journal of Heart Failure

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀